You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The two new grants add to a $1.5 million Phase II SBIR grant the company received from the National Institute of General Medical Sciences last year.
The Seattle-based firm has won two grants each worth $1.9 million to develop proximity ligation assays with applications in cytogenetics.
The newly CE-IVD-marked devices are part of the company's DNA/RNA Shield line of sample collection, preservation, and transportation products.
The firm's Nanotrap virus particles provide an alternative to RNA extraction kits and could help improve detection for respiratory viruses, including SARS-CoV-2.
The submission data highlights Parsortix's ability to harvest circulating tumor cells from metastatic breast cancer patient blood samples for downstream analysis.
Under the non-exclusive deal, Oxford Nanopore can include the technology, which targets long DNA fragments, in its nanopore sequencing products.
Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.
The company's technology uses CRISPR to deplete unwanted nucleic acid sequences from NGS libraries, leaving behind targets of interest.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
The Tokyo-based firm is looking to expand into the US market following a recent ¥700 million ($6.6 million) Series B financing round.
The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
The single-cell genomics firm's agreements with multiple companies will cover Japan, South Korea, Taiwan, Australia, and New Zealand.
An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.
UK-based ATDBio will develop new oligonucleotide-tagged microbeads for use in droplet-based single-cell RNA sequencing, to be evaluated by researchers at Oxford.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
The "EV Click Chip" process involves collecting and purifying extracellular vesicles from a blood sample before performing RT-ddPCR to identify up to 10 early-stage HCC biomarkers.
Color Genomics' kit is designed for the unmonitored self-collection of nasal swab specimens for SARS-CoV-2 testing.
Golden Gateway, which operates throughout the Asia Pacific region, will exclusively distribute UST's linked read library preparation kit in Australia.
Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.